Vera Therapeutics, Inc. Class A VERA 深 滬

Vera Therapeutics股价涨3.15%，核心药物监管进展成驱动

经济观察网 Vera Therapeutics, Inc.核心药物阿他西普监管路径明确，带动股价上涨，后续试验数据公布将影响其后续发展。 股票近期走势： Ve...

06-12 23:04

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics granted inducement awards, including stock options and RSUs, to 10 new employees under the 2024 Inducement Plan on June 2, 2026. The stock options, totaling 28,800 shares, and RSUs, totaling 14,150 shares, have an exercise price of $31.26 per share, based on Vera's closing price on June 2, 2026. Both options and RSUs vest over four years, with options vesting monthly after the first anniversary and RSUs vesting annually on speci...

06-05 20:05

Vera Moves Up Key FDA Review Timeline for Kidney Disease Drug, Expects Critical Trial Results in Third Quarter of 2026

Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced it has aligned with the

06-02 19:15

Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

Vera Therapeutics announced alignment with the FDA on an earlier ORIGIN 3 eGFR analysis for atacicept in IgAN, now expected in Q3 2026. The company plans to submit an sBLA for full approval in Q4 2026, with potential approval in 2027. Atacicept, targeting BAFF and APRIL, has shown significant proteinuria reduction and eGFR stabilization in Phase 2b and 3 trials. The revised timeline aims to accelerate full approval for this potential first-in-cla...

06-02 11:00

美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价

今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元

05-18 11:48

Evercore ISI Group Maintains Outperform on Vera Therapeutics, Lowers Price Target to $91

Evercore ISI Group analyst Gavin Clark-Gartner maintains Vera Therapeutics (NASDAQ:VERA) with a Outperform and lowers the price target from $95 to $91.

05-16 01:39

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics, Inc. announced on May 4, 2026, that its Compensation Committee granted inducement awards, including non-qualified stock options for 40,250 shares and RSUs for 20,125 shares, to 10 new employees under the 2024 Inducement Plan. The stock options have an exercise price of $35.51 per share, vesting over four years, with 25% on the first anniversary and the remainder monthly over 36 months. RSUs vest annually over four years. Vera T...

05-08 20:05

Vera Therapeutics Q1 EPS $(1.69) Misses $(1.34) Estimate

Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(1.34) by 26.12 percent. This is a 108.64 percent decrease over losses of $(0.81) per share

05-07 20:29

财报速睇 | Vera Therapeutics, Inc. Class A 2026财年Q1营收0.00亿美元，同比增长0.0%；归母净利润亏损1.21亿美元，同比亏损扩大132.7%

华盛资讯5月7日讯，Vera Therapeutics, Inc. Class A公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比增长0.0%，归母净利润亏损1.21亿美元，同比亏损扩大132.7%。

05-07 20:14

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04-10 20:30